SIGMA A2754-100MG 腺苷-5′-二磷酸钠盐 20398-34-9
文献支持

SIGMA A2754-100MG 腺苷-5′-二磷酸钠盐

20398-34-9
收藏
  • ¥167
  • Sigma-Aldrich
  • 进口
  • A2754-100MG
  • 2025年08月20日
    avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 保存条件

      −20°C

    • 保质期

      根据瓶身LOT号查询

    • 英文名

      Adenosine 5′-diphosphate sodium salt

    • 库存

      有现货

    • 供应商

      浙江羽翔生物科技有限公司

    • CAS号

      20398-34-9

    • 规格

      100MG

    属性

    Product Name

    腺苷-5′-二磷酸 钠盐, bacterial, ≥95% (HPLC)

    生物来源

    bacterial

    质量水平

    300

    方案

    ≥95% (HPLC)

    表单

    powder

    溶解性

    water: 50 mg/mL, clear to hazy, colorless

    储存温度

    −20°C

    SMILES字符串

    [Na].Nc1ncnc2n(cnc12)C3OC(COP(O)(=O)OP(O)(O)=O)C(O)C3O

    InChI

    1S/C10H15N5O10P2/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(24-10)1-23-27(21,22)25-26(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1

    InChI key

    XTWYTFMLZFPYCI-KQYNXXCUSA-N

    基因信息

    human ... HSP90AA1(3320), P2RY1(5028)

    一般描述

    5′-二磷酸腺苷(ADP)是一种通过 FOF1-ATP 合酶转化为 ATP 而参与能量储存和核酸代谢的腺嘌呤核苷酸。ADP也可通过单磷酸腺苷酸(AMP)的腺苷酸激酶催化反应得到。ADP是一种血小板激动剂,由血小板致密颗粒分泌。它通过其与ADP受体P2Y1和P2Y12的相互作用影响血小板活化。ADP在通过ecto-ADP酶转化为腺苷后,通过腺苷受体抑制血小板活化。

    应用

    5′-二磷酸腺苷钠盐已用作:
    • 血小板聚集的阳性对照,用聚焦仪分析纯化解聚素的抗血小板活性。
    • 制备原液以进行线粒体应激实验。
    • 流式细胞术分析中的阳性对照品,用于研究五聚体C反应蛋白(pCRP)和单体CRP(mCRP)对血小板CD62p(P-选择素)表达的影响。
    • 血小板激动剂,刺激血小板聚集。

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献

    In vitro and in vivo investigation of osteogenic properties of self-contained phosphate-releasing injectable purine-crosslinked chitosan-hydroxyapatite constructs.

    Scientific reports (2020-07-16)
    Kaushar Jahan, Garthiga Manickam, Maryam Tabrizian, Monzur Murshed
    PMID32665560
    摘要

    Bone fracture repair is a multifaceted, coordinated physiological process that requires new bone formation and resorption, eventually returning the fractured bone to its original state. Currently, a variety of different approaches are pursued to accelerate the repair of defective bones, which include the use of 'gold standard' autologous bone grafts. However, such grafts may not be readily available, and procedural complications may result in undesired outcomes. Considering the ease of use and tremendous customization potentials, synthetic materials may become a more suitable alternative of bone grafts. In this study, we examined the osteogenic potential of guanosine 5'-diphosphate-crosslinked chitosan scaffolds with the incorporation of hydroxyapatite, with or without pyrophosphatase activity, both in vitro and in vivo. First, scaffolds embedded with cells were characterized for cell morphology, viability, and attachment. The cell-laden scaffolds were found to significantly enhance proliferation for up to threefold, double alkaline phosphatase activity and osterix expression, and increase calcium phosphate deposits in vitro. Next, chitosan scaffolds were implanted at the fracture site in a mouse model of intramedullary rod-fixed tibial fracture. Our results showed increased callus formation at the fracture site with the scaffold carrying both hydroxyapatite and pyrophosphatase in comparison to the control scaffolds lacking both pyrophosphatase and hydroxyapatite, or pyrophosphatase alone. These results indicate that the pyrophosphatase-hydroxyapatite composite scaffold has a promising capacity to facilitate bone fracture healing.

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥99
    上海鹿森生物工程有限公司
    2025年06月28日询价
    ¥330
    浙江羽翔生物科技有限公司
    2025年07月06日询价
    ¥180
    嘉兴亦高医疗器械有限公司
    2025年12月11日询价
    文献支持
    SIGMA A2754-100MG 腺苷-5′-二磷酸钠盐 20398-34-9
    ¥167